WuXi Biologics
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic disc… Read more
WuXi Biologics (WXIBF) - Total Liabilities
Latest total liabilities as of June 2025: $11.37 Billion USD
Based on the latest financial reports, WuXi Biologics (WXIBF) has total liabilities worth $11.37 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
WuXi Biologics - Total Liabilities Trend (2014–2024)
This chart illustrates how WuXi Biologics's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
WuXi Biologics Competitors by Total Liabilities
The table below lists competitors of WuXi Biologics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jones Lang LaSalle Incorporated
NYSE:JLL
|
USA | $9.88 Billion |
|
Yankuang Energy Group Co Ltd
SHG:600188
|
China | CN¥313.84 Billion |
|
Thomson Reuters Corporation Common Shares
NASDAQ:TRI
|
USA | $6.03 Billion |
|
Valley National Bancorp 8.250% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series C
PINK:VLYPN
|
USA | $56.33 Billion |
|
Somnigroup International Inc.
NYSE:SGI
|
USA | $8.41 Billion |
|
Clorox Co.
LSE:0I0J
|
UK | $5.58 Billion |
|
Logitech International SA
NASDAQ:LOGI
|
USA | $1.76 Billion |
|
Coal India Limited
NSE:COALINDIA
|
India | ₹1.59 Trillion |
Liability Composition Analysis (2014–2024)
This chart breaks down WuXi Biologics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how WuXi Biologics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for WuXi Biologics (2014–2024)
The table below shows the annual total liabilities of WuXi Biologics from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.50 Billion | -8.42% |
| 2023-12-31 | $12.56 Billion | -5.94% |
| 2022-12-31 | $13.35 Billion | +17.88% |
| 2021-12-31 | $11.33 Billion | +40.45% |
| 2020-12-31 | $8.06 Billion | +71.35% |
| 2019-12-31 | $4.71 Billion | +236.41% |
| 2018-12-31 | $1.40 Billion | +69.65% |
| 2017-12-31 | $824.60 Million | -51.91% |
| 2016-12-31 | $1.71 Billion | +41.61% |
| 2015-12-31 | $1.21 Billion | +357.15% |
| 2014-12-31 | $264.84 Million | -- |